Immunis
Latest round
- Series A
Last raised
- Oct 2024
Total raised
- $29M
Investors
- 5
About Immunis
Based in California and founded in 2019, Immunis, Inc. operates as a biotechnology company providing treatment for age- and disease-related immune decline. In June 2024, Immunis, Inc. As of 2023, the chief science officer is Tom Lane, and the chairman is Hans S. Keirstead of the company. Immunis provides a technology known as a steam, which is a novel method to grow human stem cells for clinical use in improving immune system development, modulation, and health. The company’s technology is used for treating muscle atrophy, metabolic and vascular function, and tissue inflammation in the human body. As of 2023, the company serves industries such as biotechnology, pharmaceuticals, healthcare, and applied science.
Who invested in Immunis
5 investors across 3 rounds
See all investors in Immunis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immunis
Who invested in Immunis?
Immunis has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immunis raised?
Immunis has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Immunis last raise money?
Immunis's most recent round on record is a Series A, in Oct 2024.
What does Immunis do?
Based in California and founded in 2019, Immunis, Inc.
Where is Immunis headquartered?
Immunis is headquartered in Irvine, US.
Which VCs invest in companies like Immunis?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Immunis's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Immunis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.